
自引率: 2.9%
被引量: 3693
通过率: 暂无数据
审稿周期: 暂无数据
版面费用: 暂无数据
国人发稿量: 2
投稿须知/期刊简介:
Published by Informa Pharmaceutical Science (formerly Ashley Publications). ISSN: 1474-0338.<br /><br />Expert Opinion on Drug Safety (EODS) is a new bimonthly journal providing comprehensive coverage of the safety of new and established drug therapies. With the ever-expanding armamentarium of drugs and drug therapies available, rational pharmacotherapy today is a complex art. At the forefront of this problem is the need to provide the most effective drug regimen whilst avoiding any adverse drug reactions. From the first point of concept to establishment on the market, monitoring the safety of a drug is critical to a drug's development and commercialisation. With pharmaceutical pipelines burgeoning and further growth of medicines likely in the post-genomic era, there is rapid expansion in the quantity of primary data relating to drug safety. Through systematic review and evaluation, Expert Opinion on Drug Safety seeks to unravel this vast amount of information and provide clear and informed guides to this increasingly important area.
期刊描述简介:
由Informa Pharmaceutical Science出版(原Ashley Publications)。ISSN: 1474 - 0338。 《药物安全专家意见》(EODS)是一份新出版的双月刊,全面报道新药物和现有药物治疗的安全性。随着药物和药物治疗手段的不断发展,今天的合理药物治疗是一门复杂的艺术。这个问题的首要问题是需要提供最有效的药物治疗方案,同时避免任何药物不良反应。从概念的第一点到市场的建立,监测药物的安全性对药物的开发和商业化至关重要。在后基因组时代,随着药物管道的蓬勃发展和药物的进一步发展,与药物安全性有关的原始数据量迅速增加。通过系统的审查和评估,药品安全专家意见力求揭示这一庞大的信息,并为这一日益重要的领域提供明确和知情的指导。
-
Assessing the risk of acute kidney injury associated with a four-drug regimen for heart failure: a ten-year real-world pharmacovigilance analysis based on FAERS events.
被引量:- 发表:1970
-
Reassessment of pioglitazone and bladder cancer based on FAERS database.
被引量:- 发表:1970
-
From common to unreported: a real-world study of adverse events to duloxetine in the treatment of osteoarthritis.
被引量:- 发表:1970
-
Investigating drug-induced urinary retention: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024.
被引量:- 发表:1970
-
Toxicity profiles associated with EGFR-TKIs combined with angiogenesis inhibitors in non-small cell lung cancer: an epidemiological surveillance analysis of the FDA adverse event reporting system.
被引量:- 发表:1970